The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis

Hendy Kristyanto, Sagrario Rey Torre, Anna Cunney, Kristina Dunder, Margareta Bego, Bruno Sepodes, Thomas Castelnovo

Open source

DOI: 10.1093/bjd/ljaf259
Published: 2025-06-28
Container: British Journal of Dermatology
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/bjd/ljaf259,
  title = {The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis},
  author = {Hendy Kristyanto and Sagrario Rey Torre and Anna Cunney and Kristina Dunder and Margareta Bego and Bruno Sepodes and Thomas Castelnovo},
  year = {2025},
  journal = {British Journal of Dermatology},
  doi = {10.1093/bjd/ljaf259},
  url = {https://doi.org/10.1093/bjd/ljaf259}
}

RIS

TY  - JOUR
TI  - The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis
AU  - Hendy Kristyanto
AU  - Sagrario Rey Torre
AU  - Anna Cunney
AU  - Kristina Dunder
AU  - Margareta Bego
AU  - Bruno Sepodes
AU  - Thomas Castelnovo
PY  - 2025
JO  - British Journal of Dermatology
DO  - 10.1093/bjd/ljaf259
UR  - https://doi.org/10.1093/bjd/ljaf259
ER  -

APA

Kristyanto, H., Torre, S. R., Cunney, A., Dunder, K., Bego, M., Sepodes, B., & Castelnovo, T. (2025). The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf259

Source records

crossref · retrieved 2026-09-27T12:41:15.156Z